secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-01-16T23:59:59+00:00
Accession:  0000950170-25-006028
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi adds Eric Bjerkholt to board; board size increases to six
--------------------------------------------------------------------

- Eric Bjerkholt appointed as Class II director effective Jan 27, 2025; board expands from five to six.
- Bjerkholt is CFO of Mirum Pharmaceuticals; previously CFO at Chinook, Aimmune, Sunesis.
- He will serve on Audit and Compensation Committees; receives initial option grant of 42,000 shares vesting over 3 years.
- Company updated investor deck for J.P. Morgan Healthcare Conference; no specific pipeline details disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025006028/0000950170-25-006028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025006028/mgx-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-006028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer